Try our beta test site
IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...

A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail Gleevec

This study has been completed.
Information provided by (Responsible Party):
New Mexico Cancer Care Alliance Identifier:
First received: November 3, 2005
Last updated: September 18, 2011
Last verified: December 2009

1.0 OBJECTIVES 1.1 To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease.

1.2 To determine the toxicity associated with this therapy.

Condition Intervention Phase
Leukemia, Other
Drug: Gleevec and Arsenic Trioxide
Phase 2

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: Open Label
Primary Purpose: Treatment
Official Title: A Phase II Study of Gleevec and Arsenic Trioxide in Patients With CML Who Fail to Achieve a Complete Response to Initial Gleevec Treatment

Resource links provided by NLM:

Further study details as provided by New Mexico Cancer Care Alliance:

Primary Outcome Measures:
  • To test the activity of arsenic trioxide in combination with imatinib in patients with CML with cytogenetic evidence of residual disease [ Time Frame: 2 years ]

Secondary Outcome Measures:
  • To determine the toxicity associated with this therapy [ Time Frame: 2 years ]

Enrollment: 6
Study Start Date: April 2004
Study Completion Date: March 2006
Primary Completion Date: April 2005 (Final data collection date for primary outcome measure)
Intervention Details:
    Drug: Gleevec and Arsenic Trioxide
    Pts. who fit the inclusion criteria, & were on imatinib, 400 mg/day, will be treated with a month of imatinib at 800 mg/d in divided doses (400mg bid) & then started on arsenic trioxide. Pts. already on imatinib 800 mg/day may be started on arsenic trioxide. Pts. unable to tolerate 800 mg/d should be treated at the max. dose tolerated above 400 mg/d. A total of 16 weeks of arsenic trioxide treatment will be administered (15 weeks of maintenance). Pts. are to continue on imatinib 800 mg/day,(or the max. tolerated dose) while receiving the arsenic trioxide. If a pt. has been taken off the arsenic trioxide, they should be continued on gleevec 800 mg per day (or the maximum tolerated dose) until there is evidence of progression of disease.
Detailed Description:
  • Chronic myelogenous leukemia (CML) results from the clonal expansion of immature myeloid cells with the t (9,22) (Ph) translocation, that encodes the constitutively active tyrosine kinase oncogene, bcr/abl. Patients with chronic phase CML are currently being treated with either hemopoetic stem cell transplantation (HSCT), or with the recently approved tyrosine kinase inhibitor, imatinib. Previous data, using interferon in patients with CML, has shown that patients who do not achieve a major cytogenetic response (defined as >35% Ph+) have a shortened survival. These patients are often considered for HSCT. However, due to constraints of age, suitable donor, and patient choice, only a minority of patients will undergo this potentially curative procedure.
  • The aim of this study is to create a uniform approach to the treatment of CML in New Mexico, with an aim of achieving complete cytogenetic response as the primary goal. A graded approach will be taken, starting out with the standard treatment (imatinib 400 mg per day), and then in patients identified as poor responders an imatinib, and arsenic combination will be offered to patients. It is hoped to find a complete cytogenetic response that exceeds the ~20% response with gleevec 800mg per day.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion criteria:

  • All patients, 18 years of age or older, with a diagnosis of CML.
  • Patients must have a life expectancy of at least 12 weeks.
  • Patients must have an ECOG performance status of 0-2.
  • Patients must sign an informed consent.
  • Patients should have adequate hepatic function with a total bilirubin < 2 mg/dl and SGOT or SGPT < two times the upper limit of normal, and adequate renal function as defined by a serum creatinine < 1.5 x upper limit of normal.
  • Patients with CML in chronic phase on gleevec as first line therapy who fulfill the following criteria:
  • Failure to achieve a complete hematologic response (CHR) after 3 months of therapy (hematologic resistance)
  • Failure to achieve a complete cytogenetic response (CGCR) after > 9 months of therapy.
  • Cytogenetic relapse, defined as an increase in the Ph+ cells by at least 30%.
  • Hematologic relapse defined as the appearance of any of the following, confirmed by a second determination > 1 month later:

    • WBC count >20, 000,
    • Platelet count >600,000,
    • Progressive splenomegaly > 5 cm below the left intercostals margin,
    • >5% myelocytes and/or metamyelocytes in the peripheral blood,
    • Blasts or promyelocytes in the peripheral blood

Exclusion Criteria:

  • Pregnant women or nursing mothers are not eligible for this trial. Patients of child bearing potential must use adequate contraception.
  • Patients may receive no other concurrent chemotherapy or radiation therapy during this trial.
  • Patients with severe medical problems such as uncontrolled diabetes mellitus or cardiovascular disease or active infections are not eligible for this trial.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00250042

United States, New Mexico
University of New Mexico
Albuquerque, New Mexico, United States, 87131
New Mexico Cancer Care Associates
Santa Fe, New Mexico, United States, 87505
Sponsors and Collaborators
New Mexico Cancer Care Alliance
Principal Investigator: Ian Rabinowitz, MD University of New Mexico
  More Information

Responsible Party: New Mexico Cancer Care Alliance Identifier: NCT00250042     History of Changes
Other Study ID Numbers: 0604C
Study First Received: November 3, 2005
Last Updated: September 18, 2011

Additional relevant MeSH terms:
Arsenic trioxide
Imatinib Mesylate
Antineoplastic Agents
Protein Kinase Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action processed this record on April 26, 2017